Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;60(3):393-395.
doi: 10.1038/s41409-024-02476-z. Epub 2024 Nov 18.

Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice

Michelle M Chin  1 , John S Tamaresis  2 , Laura J Johnston  3 , Robert Lowsky  3 , Everett Meyer  3 , Lori Muffly  3 , Parveen Shiraz  3 , Matthew J Frank  3 , Andrew R Rezvani  3 , Sushma Bharadwaj  3 , Wen-Kai Weng  3 , Judith A Shizuru  3 , Sally Arai  4
Affiliations

Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice

Michelle M Chin et al. Bone Marrow Transplant. 2025 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Demographic data and outcomes of patients who received BEL combination therapy.
a Baseline patient characteristics. b List of all belumosudil (BEL) combination regimens in the cohort. c Best overall response rate (ORR) stratified by BEL combination regimen at one year.
See this image and copyright information in PMC

References

    1. Hamilton BK. Updates in chronic graft-versus-host disease. Hematol Am Soc Hematol Educ Program. 2021;2021:648–54. 10.1182/hematology.2021000301 - PMC - PubMed
    1. Martini DJ, Chen YB, DeFilipp Z. Recent FDA approvals in the treatment of graft-versus-host disease. Oncologist 2022;27:685–93. 10.1093/oncolo/oyac076 - PMC - PubMed
    1. Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazarvan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the rockstar study. Blood 2021;138:2278–89. 10.1182/blood.2021012021 - PMC - PubMed
    1. Przepiorka D, Le RQ, Ionan A, Li R-J, Wang Y-H, Gudi R, et al. FDA approval summary: Belumosudil for adult and pediatric patients 12 years and older with chronic GVHD after two or more prior lines of systemic therapy. Clin Cancer Res. 2022;28:2488–92. 10.1158/1078-0432.Ccr-21-4176 - PMC - PubMed
    1. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood 2015;125:606–15. 10.1182/blood-2014-08-551994 - PMC - PubMed

LinkOut - more resources